BioSpace News Archive

BetterLife Pharma Inc. an emerging biotech company, is pleased to announce that Patrick Kroupa and Justin Kirkland, two industry leaders in psychedelic therapeutics, have joined the Company.

Molina Healthcare, Inc. (NYSE: MOH) today announced details for the release of its results for the fourth quarter and year ended December 31, 2020.

OraSure Technologies, Inc. announced that its OMNIgene®·ORAL collection device was included in the U.S. Food and Drug Administration Emergency Use Authorization amendment granted to 3B BlackBio Biotech, one of the leading suppliers and developers for RT-PCR diagnostic assays in India.

Dr. Gerard A. Silvestri of Medical University of South Carolina Named Principal Investigator

Safety needles can be characterized as an empty bore needle which is considered to decrease or lessen the likelihood of a skin cut harm to the specialist.

Use of orthopedic imaging equipment is highly crucial for diagnosing and treating injuries, diseases, and ailments related to bone, cartilage, and associated portions of the body.

Noise anxiety in pets is a phobia or strong feeling of fear around loud noises, such as sounds from fireworks or thunderstorms.

-- VUI-202012/01 Variant May Increase SARS-CoV-2 Transmissibility by 70% -- -- Controls to be Used to Develop, Verify and Validate Tests that Identify More Transmissible Variant --

Misonix, Inc. (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that it will be participating in the 39 th Annual J.P. Morgan Healthcare Conference. Misonix Chief Executive Officer, Stavros Vizirgianakis, along with Joe Dwyer, Misonix Chief Financial Officer, will be making a virtual company presentation on Thursday, January 14

No royalty payments due for 18-24 months Proceeds will be allocated to support regulatory activities associated with the Companys development pipeline, including funding the recently initiated pivotal clinical trial for crofelemer for cancer therapy-related diarrhea (CTD), for which patient enrollment is progressing